Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/ <scp>KEYNOTE</scp> ‐775-Reference-Cited by-同舟云学术

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/ KEYNOTE ‐775

Published:2022-07-26 Issue:10 Volume:113 Page:3489-3497
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Yonemori Kan¹^ORCID,Yunokawa Mayu²,Ushijima Kimio³,Sakata Jun⁴,Shikama Ayumi⁵,Minobe Shinichiro⁶,Usami Tomoka⁷,Enomoto Takayuki⁸,Takehara Kazuhiro⁹^ORCID,Hasegawa Kosei¹⁰^ORCID,Yamagami Wataru¹¹,Yamamoto Keiko¹²,Han Shirong¹²,Dutta Lea¹³,Orlowski Robert¹⁴,Miura Takuma¹⁵,Makker Vicky¹⁶,Fujiwara Keiichi¹⁰

Affiliation:

1. National Cancer Center Hospital Tokyo Japan

2. Cancer Institute Hospital of JFCR Tokyo Japan

3. Kurume University Hospital Fukuoka Japan

4. Aichi Cancer Center Hospital Nagoya Japan

5. University of Tsukuba Hospital Ibaraki Japan

6. Hokkaido Cancer Center Sapporo Japan

7. Ehime University Hospital Toon Japan

8. Niigata University Medical & Dental Hospital Niigata Japan

9. National Hospital Organization Shikoku Cancer Center Matsuyama Japan

10. Saitama Medical University International Medical Center Saitama Japan

11. Keio University Hospital Tokyo Japan

12. MSD K.K. Tokyo Japan

13. Eisai Inc. Woodcliff Lake New Jersey USA

14. Merck & Co., Inc. Rahway New Jersey USA

15. Eisai Co., Ltd. Tokyo Japan

16. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center New York New York USA

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15436

Reference17 articles.

1. Clinical statistics of gynecologic cancers in Japan

2. Center for Cancer Control and Information Services NCC.Monitoring of cancer incidence in Japan ‐ Survival 2009–2011 report 2020.2020.

3. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms

4. Merck's KEYTRUDA® (pembrolizumab) receives five new approvals in Japan including in advanced non‐small cell lung cancer as adjuvant therapy for melanoma and in advanced microsatellite instability‐high tumors.2019.https://www.merck.com/news/mercks‐keytruda‐pembrolizumab‐receives‐five‐new‐approvals‐in‐japan‐including‐in‐advanced‐non‐small‐cell‐lung‐cancer‐nsclc‐as‐adjuvant‐therapy‐for‐melanoma‐and‐in‐advanced‐microsa/. Accessed October 18 2021.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of pembrolizumab and dostarlimab in advanced endometrial carcinoma: a systematic review;Discover Medicine;2024-09-10

2. Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway;Cancers;2024-05-14

3. Systematic review of the efficacy and safety of lenvatinib in various solid tumors;Immunopharmacology and Immunotoxicology;2024-04-23

4. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system;Japanese Journal of Clinical Oncology;2024-01-20

5. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients;Frontiers in Oncology;2024-01-04